The final module of the Thyroid Pharmacology Series addresses the specialized pharmacological contexts that extend beyond the core hypothyroidism and hyperthyroidism management covered in the preceding modules. Radioactive iodine I-131 is examined here as both the definitive ablative therapy for differentiated thyroid cancer (DTC) and the substrate for rhTSH (recombinant human thyroid-stimulating hormone)-stimulated staging and follow-up. Thyroid-stimulating hormone suppression therapy for DTC involves nuanced risk-stratified target selection that carries measurable cardiovascular and skeletal consequences requiring active management. The emerging landscape of targeted pharmacotherapy for radioiodine-refractory and medullary thyroid cancers encompasses multi-kinase inhibitors, BRAF-directed combinations, and RET fusion inhibitors. Amiodarone-induced thyroid disease presents a particularly complex pharmacological problem because of the drug’s dual effects on thyroid hormone synthesis and metabolism, the difficulty of distinguishing type 1 from type 2 thyrotoxicosis, and the frequent necessity of managing both conditions without discontinuing a life-sustaining antiarrhythmic. Finally, pregnancy creates the most demanding physiological environment for thyroid pharmacology, with competing risks of fetal harm from both undertreated maternal thyroid disease and drug teratogenicity requiring careful agent selection and timing.
Iodine-131 (I-131) is a beta-gamma emitter with a physical half-life of 8.02 days, concentrated in thyroid follicular cells and differentiated thyroid cancer metastases by the sodium-iodide symporter (NIS). The primary therapeutic effect derives from beta particles, which have a tissue range of 1–2 mm and deposit most of their energy within the follicular cell that concentrated them, producing double-strand deoxyribonucleic acid (DNA) breaks and progressive follicular destruction over 6–12 weeks after administration. Gamma radiation emitted by I-131, while therapeutically minimal, enables whole-body scintigraphy (RAI scan) to map functioning thyroid remnant and metastatic disease. After total thyroidectomy for differentiated thyroid cancer, residual normal thyroid tissue (the thyroid remnant) competes with metastatic disease for RAI uptake; ablation of the remnant both serves as a staging procedure and eliminates this competitive uptake so that subsequent post-treatment scans and serum thyroglobulin measurements become interpretable as markers of persistent or recurrent disease.1,2
Two approaches to radioactive iodine dosing are used for differentiated thyroid cancer (DTC) remnant ablation. The empirical fixed-dose approach administers a standard activity (typically 30–100 mCi for low-risk remnant ablation, 100–200 mCi for adjuvant therapy in intermediate-to-high-risk disease) without individualized dosimetry. Dosimetry-guided approaches measure whole-body retention at 24 and 48 hours post-tracer administration and calculate the maximum tolerable activity that avoids bone marrow toxicity (whole-body retention below 2 Gy) and radiation pneumonitis in diffuse pulmonary metastases (total lung dose below 25–27 Gy). The HiLo trial demonstrated that low-activity I-131 (1.1 GBq, approximately 30 mCi) is non-inferior to high-activity I-131 (3.7 GBq, approximately 100 mCi) for remnant ablation in low-risk DTC when combined with rhTSH stimulation, with substantially reduced radiation exposure and equivalent 3-year remission rates. For intermediate-to-high-risk disease with known metastases, higher activities are standard, and dosimetry guidance is particularly valuable when renal impairment, advanced age, or diffuse pulmonary metastases alter the clearance kinetics of I-131.1,2
Thyroid-stimulating hormone (TSH) stimulation above 30 mIU/L is required before RAI administration to maximize NIS expression in remnant and metastatic thyroid tissue, since NIS transcription is TSH-dependent. This threshold can be achieved by either thyroid hormone withdrawal or rhTSH injection. Thyroid hormone withdrawal requires stopping levothyroxine for 4 weeks (or liothyronine, if substituted, for 2 weeks) and produces sustained hypothyroidism with TSH typically above 50 mIU/L but causes significant quality-of-life impairment including fatigue, cold intolerance, cognitive slowing, and fluid retention. Recombinant human thyroid-stimulating hormone, thyrotropin alfa (Thyrogen), is administered as 0.9 mg intramuscular injection on two consecutive days, with RAI given on the third day; serum TSH peaks at 24 hours post-injection (typically above 100 mIU/L) and returns to baseline by 72 hours. The THYROGEN (thyrotropin alfa) protocol maintains euthyroidism throughout, preserves quality of life, reduces radiation to the body as a whole (since normal tissues are not stimulated to retain I-131 as long), and is approved for remnant ablation in low-to-intermediate-risk DTC. A low-iodine diet (below 50 mcg iodine/day for 1–2 weeks before and until 2 days after RAI) is required regardless of stimulation method to maximize radioiodine uptake by depleting the competing stable iodine pool.1,3
rhTSH (thyrotropin alfa) is equivalent to withdrawal for remnant ablation in low-to-intermediate-risk DTC and is preferred to avoid hypothyroidism. Thyroid hormone withdrawal remains necessary in high-risk patients with known metastases requiring high-dose RAI with dosimetry, where persistent body retention data must reflect the patient’s actual pharmacokinetics in a euthyroid-depleted iodine state. Withdrawal is also required when rhTSH is not available. The choice should be made in multidisciplinary consultation with nuclear medicine and endocrinology.
Levothyroxine in supraphysiological doses suppresses thyroid-stimulating hormone (TSH) below the lower limit of the reference range (below 0.5 mIU/L) in patients with differentiated thyroid cancer, exploiting the trophic dependence of thyroid cancer cells on TSH for proliferation and survival. The pharmacological basis is well established: TSH drives expression of thyroid-specific growth factors, sodium-iodide symporter (NIS), thyroglobulin, and thyroid peroxidase (TPO) in residual cancer cells, so its suppression reduces the proliferative stimulus and the likelihood of recurrence. However, TSH suppression is not uniformly applied; the 2015 American Thyroid Association (ATA) guidelines stratify TSH targets by ATA risk tier, disease response category, and treatment phase. In the initial post-treatment phase for high-risk patients with gross extrathyroidal extension, known distant metastases, or incomplete resection, TSH suppression below 0.1 mIU/L is recommended. In the initial phase for intermediate-risk disease, TSH 0.1–0.5 mIU/L is targeted. For low-risk disease after successful ablation and two years of follow-up without evidence of disease, the TSH target is relaxed to 0.5–2.0 mIU/L, accepting that the benefit of continued suppression is marginal in patients at low recurrence risk and does not outweigh the cumulative long-term harm.1,4
The harms of prolonged TSH suppression are dose- and duration-dependent and affect two organ systems predominantly. In the skeleton, sustained subclinical thyrotoxicosis from TSH suppression reduces bone mineral density (BMD) through increased osteoclast activity driven by thyroid hormone excess, predominantly affecting cortical bone in postmenopausal women who lack the estrogen counter-regulation that attenuates this effect in premenopausal women. The cumulative BMD loss over years of suppression is clinically significant and reaches the threshold for osteoporotic fracture risk in a subset of older patients. Dual-energy X-ray absorptiometry (DXA) screening and appropriate antiresorptive therapy (bisphosphonates or denosumab) should be considered in postmenopausal women on sustained TSH suppression below 0.1 mIU/L. In the cardiovascular system, TSH suppression accelerates heart rate, shortens the PR (pulse-to-R-wave) interval, increases left ventricular mass, and raises the risk of atrial fibrillation (AF) by two-to-threefold in older patients. Patients over 60 on suppressive therapy should be monitored for AF on a scheduled basis, and cardiovascular risk factors should be aggressively managed. De-escalation of suppression at earliest clinical opportunity is the primary preventive strategy for both skeletal and cardiovascular harm.1,4
Response-to-therapy stratification reclassifies patients during follow-up based on structural and biochemical outcomes and allows dynamic adjustment of TSH targets. Excellent response (negative imaging, suppressed thyroglobulin, negative anti-thyroglobulin antibodies) after initial treatment reclassifies a patient to a lower-risk category with higher TSH targets; this reclassification is clinically important because the majority of low-to-intermediate-risk patients achieve excellent response within 2 years. Indeterminate response (non-specific structural findings, low-level thyroglobulin detectable but below 10 ng/mL on stimulation) warrants maintained low-to-intermediate suppression with close surveillance. Biochemically incomplete response (rising or elevated thyroglobulin without structural disease) or structurally incomplete response (persistent or new structural disease on imaging) mandate continued aggressive suppression and consideration of additional therapy. Serum thyroglobulin measured under rhTSH stimulation every 1–2 years is the primary biochemical surveillance tool in patients without anti-thyroglobulin antibodies, which interfere with thyroglobulin immunoassay and mandate antibody trend monitoring as a surrogate.1,4
Initial high-risk (gross extrathyroidal extension, distant metastases): TSH below 0.1 mIU/L. Initial intermediate-risk: TSH 0.1–0.5 mIU/L. Low-risk after excellent response at 2 years: TSH 0.5–2.0 mIU/L (standard replacement range). All suppression decisions are re-evaluated dynamically with each 6-to-12-month follow-up incorporating structural and biochemical response data. The goal is the lowest tolerable TSH that minimizes recurrence risk without incurring preventable cardiovascular or skeletal harm.
Radioiodine-refractory differentiated thyroid cancer (RAI-refractory DTC) is defined by absent RAI uptake in metastatic lesions, progression of structural disease during or after RAI therapy, or total cumulative RAI activity above 600 mCi without complete response. Approximately 5-15% of DTC patients develop RAI-refractory disease, and this subset accounts for the majority of thyroid cancer mortality. The pharmacological basis of RAI refractoriness involves dedifferentiation of tumor cells with loss of NIS (sodium-iodide symporter) expression, driven by activating mutations in the MAPK (mitogen-activated protein kinase) pathway, most commonly BRAF (B-Raf proto-oncogene) V600E (valine-to-glutamate substitution at codon 600) and RAS (rat sarcoma viral proto-oncogene) mutations. Two multi-kinase inhibitors are FDA-approved for RAI-refractory DTC: sorafenib (DECISION trial, 2013) and lenvatinib (SELECT trial, 2015), both targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and RAF (rapidly accelerated fibrosarcoma) kinases. In the DECISION trial, sorafenib improved median progression-free survival (PFS) from 5.8 to 10.8 months versus placebo. In the SELECT trial, lenvatinib achieved median PFS of 18.3 months versus 3.6 months with placebo, with a 65% objective response rate.5,6
Medullary thyroid cancer (MTC) arises from calcitonin-secreting parafollicular C-cells, which do not concentrate radioiodine. Heritable MTC cases harbor germline mutations in the RET (rearranged during transfection) proto-oncogene; the specific codon mutation correlates with phenotypic aggressiveness and guides prophylactic thyroidectomy timing in multiple endocrine neoplasia type 2 (MEN2) kindreds. Two multi-kinase inhibitors are approved for progressive MTC: vandetanib (ZETA trial, 2011) and cabozantinib (EXAM trial, 2012), both targeting RET kinase and VEGFR. Vandetanib additionally inhibits the epidermal growth factor receptor (EGFR); cabozantinib additionally inhibits the MET (hepatocyte growth factor receptor) kinase, relevant to its efficacy in RET wild-type MTC. Serum calcitonin and carcinoembryonic antigen (CEA) serve as biomarkers for monitoring MTC treatment response.7,8
Precision oncology has transformed advanced thyroid cancer management. The BRAF inhibitor dabrafenib plus MEK (mitogen-activated protein kinase kinase) inhibitor trametinib received FDA approval in 2022 for locally advanced or metastatic BRAF V600E-mutant anaplastic thyroid cancer (ATC), the most lethal thyroid malignancy, after the ROAR (Rare Oncology Agnostic Research) basket trial demonstrated responses in approximately 69% of patients. Selective RET kinase inhibitors represent a further advance: selpercatinib received approval in 2020 for RET-fusion-positive thyroid cancer and RET-mutant MTC based on the registrational phase 1/2 trial, which demonstrated a 79% response rate in RET-mutant MTC. Pralsetinib received approval in 2020 for the same indications (ARROW trial). Both selective RET inhibitors show substantially better tolerability than broader multi-kinase inhibitors, with lower rates of hypertension, hand-foot syndrome, and hepatotoxicity, representing a shift toward mutation-guided treatment selection.7,8,9
Hypertension (60-80%): initiate antihypertensives; dose reduce if uncontrolled. Hand-foot skin reaction: sorafenib greater than lenvatinib; dose reduction for grade 3. Diarrhea: loperamide support. QT prolongation: vandetanib black box warning; baseline and serial ECG; avoid concomitant QT-prolonging agents. Hepatotoxicity: LFTs every 2-4 weeks initially. Fistula and wound healing: hold 7-10 days before and after surgery.
Amiodarone is a benzofuran iodine-rich antiarrhythmic containing 37% iodine by weight, releasing approximately 6 mg of free inorganic iodide daily from a standard 200 mg tablet, far exceeding the recommended daily iodine allowance of 150 mcg. Its pharmacokinetic profile is extraordinary: a volume of distribution of 60 L/kg, elimination half-life of 40-55 days, and extensive accumulation in adipose, hepatic, pulmonary, and thyroid tissue ensure that thyroid effects persist for months after drug discontinuation. Amiodarone causes hypothyroidism predominantly in iodine-sufficient regions through sustained Wolff-Chaikoff inhibition of thyroid hormone synthesis, and causes thyrotoxicosis primarily in iodine-deficient regions where autonomous substrate drives previously iodine-depleted glands. In any setting, amiodarone inhibits type 1 deiodinase (D1), reducing thyroxine (T4)-to-triiodothyronine (T3) conversion and raising reverse T3 (rT3), producing an expected biochemical pattern in the first 3 months: elevated free T4, low T3, high rT3, and transiently elevated thyroid-stimulating hormone (TSH). This pattern is pharmacological, not pathological, and should not prompt treatment.10,11
Amiodarone-induced thyrotoxicosis (AIT) occurs in 2-10% of treated patients and is classified into two types with distinct pathophysiology and treatment requirements. Type 1 AIT (iodine-induced Jod-Basedow thyrotoxicosis) occurs in patients with pre-existing thyroid autonomy, either unrecognized Graves disease or toxic multinodular goiter (TMNG); the iodine excess provides autonomous substrate driving unregulated thyroid hormone synthesis. Type 2 AIT is a destructive thyroiditis caused by the direct cytotoxic effects of amiodarone and its active metabolite desethylamiodarone on thyroid follicular cells, releasing preformed hormone without new synthesis; it is more common than type 1 and can occur in a structurally normal gland. Mixed forms with features of both types exist. The clinical distinction determines pharmacological approach and expected course.10,11
Differentiating AIT type 1 from type 2 guides treatment. Thyroid ultrasound with color Doppler is the most useful non-invasive discriminator: type 1 shows increased or normal vascularity reflecting active synthesis, while type 2 shows absent or markedly reduced vascularity reflecting avascular destructive thyroiditis. Radioiodine uptake is low to absent in both types due to iodine loading but is more profoundly suppressed in type 2. Interleukin-6 (IL-6) is elevated to a greater degree in type 2, reflecting the inflammatory process. Treatment of type 1 AIT uses methimazole (MMI) 40-60 mg/day, though efficacy is attenuated by high intrathyroidal iodine; potassium perchlorate 200 mg four times daily can be added where available to block iodide transport and reduce intrathyroidal iodine load. Treatment of type 2 AIT uses oral prednisone 40-60 mg/day tapered over 3 months to suppress the inflammatory destructive process. When type cannot be confidently determined, combined methimazole plus glucocorticoids is pragmatic. Amiodarone continuation versus discontinuation is a joint cardiological-endocrinological decision; in patients with life-threatening arrhythmias without an alternative, amiodarone may continue while AIT is actively treated.10,11
Type 1 (iodine-induced synthesis): pre-existing thyroid disease, hypervascularity on Doppler. Treat with high-dose methimazole plus or minus potassium perchlorate. Type 2 (destructive thyroiditis): normal or previously normal gland, avascularity on Doppler, elevated IL-6. Treat with glucocorticoids. Mixed: treat with both. Neither type requires urgent amiodarone discontinuation without cardiology consultation.
Pregnancy creates unique thyroid pharmacological challenges because normal gestational physiology mimics and overlaps with thyroid disease, drug effects extend to the fetus, and the consequences of both untreated disease and iatrogenic fetal hypothyroidism are severe. Human chorionic gonadotropin (hCG), which shares structural homology with thyroid-stimulating hormone (TSH) and binds weakly to the TSH receptor, rises steeply in the first trimester and produces TSH suppression in up to 15% of normal pregnancies; first-trimester TSH may fall below 0.1 mIU/L without pathological hyperthyroidism. Gestational transient thyrotoxicosis (GTT) is caused by this hCG-driven TSH suppression, does not represent true hyperthyroidism requiring antithyroid treatment, and resolves spontaneously by 14-20 weeks as hCG declines. Hyperemesis gravidarum is the severe end of hCG-driven thyroid stimulation, associated with TSH suppression and mildly elevated free thyroxine (T4) alongside intractable vomiting; symptomatic management with antiemetics and fluid replacement, not antithyroid drugs, is the appropriate treatment for GTT with hyperemesis. Distinguishing GTT from true Graves disease in pregnancy requires positive TRAb (thyroid-stimulating antibody, also called TSH receptor antibody), a diffuse goiter, and the absence of spontaneous resolution by 14-16 weeks.1,12
True Graves disease in pregnancy carries risks of fetal and neonatal thyrotoxicosis from transplacental transfer of maternal TRAb, preterm delivery, and intrauterine growth restriction from undertreated maternal hyperthyroidism, alongside risks of fetal hypothyroidism from excessive thionamide dosing. The goal of antithyroid therapy in pregnancy is to maintain maternal free T4 in the upper third of the normal reference range or mildly above it, using the lowest effective thionamide dose, because both thionamides cross the placenta and can suppress fetal thyroid hormone synthesis. Overtreatment causing fetal hypothyroidism is as harmful as undertreatment. Fetal heart rate above 160 beats per minute, advanced bone age, or fetal goiter on ultrasound are signs of fetal thyrotoxicosis from uncontrolled maternal TRAb; fetal hypothyroidism from overtreatment produces bradycardia and fetal goiter with normal or delayed bone age. As covered in Module 3, propylthiouracil (PTU) is preferred over methimazole (MMI) in the first trimester to avoid the MMI embryopathy syndrome during organogenesis, with transition back to MMI at 16 weeks. The lowest effective dose that maintains maternal free T4 in the upper normal range should be used; block-and-replace strategy, which exposes the fetus to higher cumulative thionamide doses, is contraindicated in pregnancy.1,12
Postpartum thyroiditis, occurring in approximately 5-9% of women in the year following delivery, follows a characteristic triphasic course of hyperthyroidism (weeks 1-4 postpartum), hypothyroidism (months 4-8 postpartum), and return to euthyroidism in most but not all women. The hyperthyroid phase is caused by destructive autoimmune thyroiditis releasing preformed hormone and is managed symptomatically with beta-blockers; antithyroid drugs are not effective and not indicated because there is no ongoing new synthesis. The hypothyroid phase may require temporary levothyroxine replacement, particularly in symptomatic women or those planning another pregnancy. Women who develop permanent hypothyroidism after postpartum thyroiditis (approximately 25-30%) have pre-existing Hashimoto disease; anti-thyroid peroxidase (anti-TPO) antibody positivity before delivery identifies those at highest risk and is the single strongest predictor of postpartum thyroiditis development.1,12
Undertreatment: maternal TSH remains suppressed, free T4 elevated above upper third of reference range. Risk: fetal tachycardia, preterm delivery, growth restriction, neonatal Graves. Overtreatment: fetal TSH rises, fetal thyroid stimulated into goiter, fetal bradycardia and delayed bone maturation. Goal: lowest thionamide dose that keeps maternal free T4 in upper third of normal or mildly above. Check TFTs every 4 weeks and adjust dose to target. TRAb measurement at 28-32 weeks predicts neonatal Graves risk if elevated above 3x upper reference limit.
Neonatal Graves disease results from transplacental transfer of maternal TRAb to the fetus, producing autonomous thyroid stimulation that persists after birth until the maternal antibodies clear. It affects approximately 1-5% of neonates born to mothers with Graves disease and can occur even when the mother is euthyroid on antithyroid therapy or after thyroid ablation, because TRAb can persist for years after thyroid destruction. The clinical presentation typically begins 3-7 days after birth as the protective effect of maternal antithyroid drugs (which cross the placenta and suppress fetal thyroid function in utero) clears, while the maternal TRAb remain active. Signs include tachycardia, irritability, poor weight gain despite hyperphagia, advanced bone age, goiter, and in severe cases exophthalmos and cardiac failure. Maternal TRAb levels measured at 28-32 weeks predict neonatal disease risk: TRAb above 3 times the upper reference limit is associated with significantly elevated neonatal risk and should prompt close neonatal monitoring including thyroid function testing at 48-72 hours of life.12,13
Management of neonatal Graves disease is pharmacologically identical in principle to management of hyperthyroidism in adults but requires neonatal dose adjustments. Methimazole (MMI) is the preferred antithyroid agent at 0.2-0.5 mg/kg/day divided every 8 hours, with dose titration guided by thyroid function tests checked every 1-2 weeks. Propylthiouracil (PTU) is generally avoided in neonates given the hepatotoxicity risk. Beta-blockade with propranolol 0.5-2 mg/kg/day divided every 8 hours controls tachycardia and adrenergic symptoms while antithyroid therapy establishes biochemical control. Lugol iodine solution is used in severe cases to rapidly reduce thyroid hormone secretion, administered as one drop three times daily but limited to short courses due to the potential for rebound thyroid stimulation. The course of neonatal Graves disease is self-limited: as maternal TRAb titers decline over 3-6 months following the neonatal period, thyrotoxicosis remits and antithyroid therapy can be progressively withdrawn. Rare cases with very high TRAb titers or concurrent neonatal thyroid autonomy may require prolonged treatment.12,13
Neonatal Graves disease may not be apparent at birth if the mother was on antithyroid drugs; the drug effect persists for 3-7 days after delivery before clearing, during which the neonate may appear euthyroid. As maternal PTU or MMI clears, TRAb-driven thyrotoxicosis emerges. Neonates born to mothers with elevated TRAb (>3x upper limit) must be observed for at least 5-7 days in hospital or with close outpatient follow-up and TSH/free T4 measured at 48-72 hours and again at 7-10 days of life. A normal newborn screen TSH does not exclude neonatal Graves disease with delayed onset.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.
doi:10.1089/thy.2015.0020Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366(18):1663–1673.
doi:10.1056/NEJMoa1108586Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91(3):926–932.
doi:10.1210/jc.2005-1651Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670–1751.
doi:10.1089/thy.2014.0028Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319–328.
doi:10.1016/S0140-6736(14)60421-9Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–630.
doi:10.1056/NEJMoa1406470Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134–141.
doi:10.1200/JCO.2011.35.5040Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383(9):825–835.
doi:10.1056/NEJMoa2005651Subbiah V, Hu MI, Wirth LJ, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021;9(8):491–501.
doi:10.1016/S2213-8587(21)00120-0Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–1421.
doi:10.1089/thy.2016.0229Bogazzi F, Bartalena L, Martino E. Approach to the patient with amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 2010;95(6):2529–2535.
doi:10.1210/jc.2010-0180Alexander EK, Pearce EN, Brent GA, et al. 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017;27(3):315–389.
doi:10.1089/thy.2016.0457van der Kaay DC, Wasserman JD, Palmert MR. Management of neonates born to mothers with Graves’ disease. Pediatrics. 2016;137(4):e20151878.
doi:10.1542/peds.2015-1878